Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatment for vitiligo shows promise in early trial

NCT ID NCT07563049

Disease control Sponsor: Kasr El Aini Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether injecting carbon dioxide gas (carboxytherapy) alongside standard narrowband UVB light therapy can improve repigmentation in people with stable vitiligo. Fifty-nine participants with symmetrical patches will receive whole-body UVB light, with carboxytherapy added on one side only. The study measures changes in skin color and certain blood markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carbon dioxide gas
What this could lead to
If it works, this could offer a better way to restore skin color in people with stable vitiligo.
What could go wrong
This is a small, early-phase trial with only 59 people. The added benefit of carboxytherapy may be small or none, and injections can cause discomfort or bruising.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

59 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects with stable non-segmental vitiligo (≥2 symmetrical patches of diameter less than 2 cm on acral or ≥ 2 symmetrical patches on non-acral sites). Subjects were stable for twelve or more months. Exclusion Criteria: * Subjects with unstable vitiligo. * Subjects with segmental vitiligo. * Pregnant females. * Severe anemia (Hb \<7 gm/dl). * Cardiac/hepatic/renal/respiratory failure. * Superficial thrombophlebitis. * Subjects with history of skin malignancy or precancerous conditions like Xeroderma pigmentosum. * Subjects with other autoimmune disorders. * Systemic drugs for vitiligo in the last 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vitiligo vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vitiligo vulgaris

Contacts and locations

Locations

  • Faculty of Medicine, Cairo University

    Cairo, El Manial, 11956, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.